Tarek Mouhieddine, Medical Oncologist, Associate Director of Translational and Correlative Research at Dana-Farber Cancer Institute, shared NEJM’s post on X, adding:
“Grateful for the opportunity to contribute this review on multiple myeloma with Dr. Kenneth Anderson.
We discuss the rapidly evolving treatment landscape and how emerging therapies are reshaping the approach to myeloma.”
Quoting NEJM’s post:
“Drs. Tarek H. Mouhieddine and Kenneth C. Anderson summarize treatment for multiple myeloma, highlighting four-drug induction therapy, evolving transplantation strategies, tailored maintenance therapy, and in relapse, earlier use of BCMA-directed immunotherapy.”
Title: Treatment Decisions in Multiple Myeloma
Authors: Tarek H. Mouhieddine, Kenneth C. Anderson
You can also read:
Myeloma Paper of the Day, September 11th, Suggested by Robert Orlowski
